Risperidone market?

Do you mean one of these?

- Market size/brands and manufacturers (global or regional)
- Regulatory approvals and current indications
- Availability: branded vs. generic forms and dosing formulations
- Competitive landscape vs. other antipsychotics

Brief overview to cover the bases:
- What it is: Risperidone is a second-generation (atypical) antipsychotic.
- Availability: Now widely available as a generic. Brand names historically include Risperdal (oral tablets and M-tab orodispersible tablets). It also comes in long-acting injectable forms in some markets (eg, Risperdal Consta; and there are other LAI risperidone products in certain regions).
- Indications: Schizophrenia (adults and adolescents), bipolar mania/mixed episodes, and irritability associated with autism in children (age ranges vary by country).
- Market dynamics: It has been a top-selling antipsychotic in the past, but the market has become more generics-driven with strong competition from other SGAs (eg, olanzapine, quetiapine, aripiprazole, ziprasidone, lurasidone, cariprazine, brexpiprazole). The share of risperidone varies by country and payer.
- Safety considerations: Metabolic effects (weight gain, lipids), hyperprolactinemia, extrapyramidal symptoms, sedation; increased mortality in elderly with dementia-related psychosis; drug interactions (notably CYP2D6 and CYP3A4).

If you can specify:
- the region or country you’re interested in, and
- whether you want current sales/market size numbers, brand vs generic status, or regulatory approvals,

I can tailor the info and, if you’d like, pull in the latest market data or provide a comparative snapshot with key competitors.